Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73618913" target="_blank" >RIV/61989592:15110/23:73618913 - isvavai.cz</a>
Result on the web
<a href="https://www.eurekaselect.com/article/123757" target="_blank" >https://www.eurekaselect.com/article/123757</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1871520622666220519102948" target="_blank" >10.2174/1871520622666220519102948</a>
Alternative languages
Result language
angličtina
Original language name
Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy
Original language description
Tumour relapse, chemotherapy resistance, and metastasis continue to be unsolved issues in cancer therapy. A recent approach has been to scrutinise drugs used in the clinic for other illnesses and modify their structure to increase selectivity to cancer cells. Chloroquine (CQ) and hydroxychloroquine (HCQ), known antimalarials, have successfully treated autoimmune and neoplastic diseases. CQ and HCQ, well-known lysosomotropic agents, induce apoptosis, downregulate autophagy, and modify the tumour microenvironment. Moreover, they affect the Toll 9/NF-κB receptor pathway, activate stress response pathways, enhance p53 activity and CXCR4-CXCL12 expression in cancer cells, which would help explain their effects in cancer treatment. These compounds can normalise the tumour associated vasculature, promote the activation of the immune system, change the phenotype of tumour-associated macrophages (from M2 to M1), and stimulate cancer-associated fibroblasts. We aim to review the historical aspects of CQ and its derivatives and the most relevant mechanisms that support the therapeutic use of CQ and HCQ for the treatment of cancer.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molecular, cellular and clinical approach to healthy ageing</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Anti-Cancer Agents in Medicinal Chemistry
ISSN
1871-5206
e-ISSN
1875-5992
Volume of the periodical
23
Issue of the periodical within the volume
10
Country of publishing house
AE - UNITED ARAB EMIRATES
Number of pages
23
Pages from-to
1122-1144
UT code for WoS article
001025442300003
EID of the result in the Scopus database
2-s2.0-85161055349